authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 4, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–5632 Filed 3–11–11; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Opportunity to Partner; Testing of Patient Compartment Seating and Restraints to Proposed Test Standard

Authority: 29 U.S.C. 669.

AGENCY: NIOSH, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of informational meeting and opportunity to partner.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH), CDC, HHS, in collaboration with the National Truck Equipment Association, Ambulance Manufacturers Division (NTEA–AMD) has developed a series of proposed ambulance component test standards. One such standard, AMD STANDARD 026—Seat, Seat Mount and Occupant Restraint Dynamic Test—Proposed (draft), seeks to improve occupant and seat retention during crash conditions. As a part of the standard development process, NIOSH will be conducting a series of tests to evaluate existing, redesigned, and/or new seating to validate the test methods proposed. It is anticipated testing will be conducted in up to three phases over approximately 15 months. NIOSH will contract with an independent test facility and provide funding for all testing, instrumentation, data collection, and data analysis. Prospective industry partners will provide the following test assets: Seating, seat retention devices, and occupant restraints. This project has three key goals: (1) To validate test and data collection methodologies proposed in AMD 026 (draft) to support standard development; (2) to support and facilitate the transition of the industry from the current seating design parameters to those proposed in SAE J2917 Surface Vehicle Recommended Practice, Occupant Restraint and Equipment Mounting Integrity—Frontal Impact System-Level Ambulance Patient Compartment, published May 2010, and SAE J2956 Surface Vehicle Recommended Practice, Occupant Restraint and Equipment Mounting Integrity—Side Impact System-Level Ambulance Patient Compartment (draft); and, (3) to develop the design and production "cost-of-change" to meet the proposed design parameters.

DATES AND TIMES: March 23, 2011, 1 p.m.–5 p.m., Eastern Standard Time (EST) March 24, 2011, 8 a.m.–12 noon, EST, by appointment. NIOSH is available to meet with individual companies for those interested in further discussion. We anticipate offering the prospective partners the opportunity to meet for 30 minutes, to ask specific questions pertinent to their situation.

ADDRESSES: Homewood Suites Indianapolis-Downtown, 211 South Meridian Street, Indianapolis, Indiana 46225, Telephone (317) 636–7992. (Coincident with the 2011 Fire Department Instructors Conference (FDIC).)

Letters of Interest: Interested manufacturers should submit a letter of interest with information about their capabilities and level of proposed participation to Jim Green at *JGreen@cdc.gov.* Letters of interest must be received by April 25, 2011.

SUPPLEMENTARY INFORMATION: NIOSH proposes a series of up to 116 tests to better understand the capabilities and limitations of currently available seating and restraints, investigate redesign or new design options, and validate the proposed test standard. As a byproduct of this effort, it is expected that NIOSH and its partners will be able to demonstrate that seating and restraints provided by partners meet the design parameters specified in AMD 026 (draft) and test requirements outlined in SAE J2917 and SAE 2956 (draft), respectively.

Prospective partners will be existing seating and/or restraint manufacturers nationally or internationally. A prospective partner need not be selling to the United States market at the time of this announcement.

Prospective partners will be required to provide test assets (seating, seat retention devices, and/or occupant restraints) free of charge in exchange for their participation in this collaborative standards development and validation effort. In return, NIOSH will cover all costs associated with testing. This includes the cost of the sled buck design and manufacture, rental of appropriate test manikins, instrumentation related to the litter, manikin, and sled buck, test execution, test data analysis, and cost data analysis.

Given the nature of the proposed change, coupled with the cost for each unit, NIOSH anticipates the need to partner with more than one manufacturer. Therefore no one manufacturer should expect to be asked to contribute all needed test assets.

In phase 1, test assets are expected to come from those in the existing product line per mutual agreement with NIOSH. In phases 2 and 3, test assets are expected to be introduced as either redesigns of existing products or new products entirely based on the results of phase 1 testing. The cost of product redesign and manufacture for phase 2 and 3 testing would be borne by the manufacturer partner(s).

Each partner will be invited to participate at the site of testing (a third party independent test facility) during the testing of its product. However, at no time will representatives from two different manufacturers be present at the same time or on the same date. As a participant, each partner will be provided with a copy of all digital video and instrumented data for use in future product development. NIOSH will retain a copy of all data but will code, to the extent possible, to prevent release of vendor specific product data. Partners will retain ownership of each test asset and will be asked to retrieve test assets once each test has been completed. All shipping and/or disposal costs of test assets to and from the independent test facility will be borne by the manufacturer partner(s).

Recognizing any change in standard or test requirement may have a coincident cost; NIOSH will also be seeking to quantify the cost of change—that is, the cost of redesigning and manufacturing to meet the proposed new test standards. In this instance, NIOSH has a separate effort in place with an independent Certified Public Accountant (CPA). Any participant or partner in this effort would be required to work with the CPA in parallel with the test program outlined above. Specifically, the partner would be required to provide the underlying cost data for each product evaluated in the test program. This would include the costs for a current or comparable pre-test or pre-standard seat, seat retention device, and occupant restraint and its companion post standard or post redesign equivalent. Prospective partners should be aware it may be possible to consider a few products within their existing product line (e.g.; entry level, mid level, and high end products). These costs may include: Per

unit cost of materials, per unit cost of labor, per unit cost of design, test and certification, etc. Data from each manufacturer will be held confidential by the CPA and coded to remove corporate identifiers. The goal is to assess the cost of change to the industry rather than to an individual product within a given manufacturers' broad product line.

Candidate companies will be evaluated based on their capability and willingness to work cooperatively to achieve the stated goals. Candidates selected will be required to enter into a Letter of Agreement spelling out the level of participation expected of each partner and the handling of data generated from the partnership. This announcement does not obligate NIOSH to enter into an agreement with any respondents. NIOSH reserves the right to establish a partnership based on the engineering analysis and capabilities found by way of this announcement or other searches, if determined to be in the best interest of the government.

NIOSH recognizes this opportunity will raise many questions for prospective partners. In order to give all involved the greatest opportunity to understand the process and project expectations, the NTEA–AMD, our collaborative partner and host standards setting body, has agreed to provide a meeting room for us to hold an informational meeting to present a broad overview of the effort and answer any resulting questions.

In order to provide us with the best opportunity to meet the needs of all prospective partners at each of these meetings; we request that all interested parties contact Jim Green, NIOSH Project Officer, by e-mail at *JGreen@cdc.gov;* or telephone (304) 285–5857, by Thursday, March 17, 2011.

CONTACT PERSON FOR MORE INFORMATION: Jim Green, NIOSH Project Officer, e-mail: *JGreen@cdc.gov;* telephone (304) 285–5857.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 7, 2011.

Tanja Popovic,

Deputy Associate Director for Science, Centers for Disease Control and Prevention.

[FR Doc. 2011–5732 Filed 3–11–11; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; Teleconference

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Pilot for State-specific Cross-Sectional Surveillance of Persons with Rare Disorders and Longitudinal Assessment of Outcomes, Funding Opportunity Announcement (FOA) DD11–004, and Pilot Longitudinal Data Collection to Inform Public Health—Fragile X Syndrome, FOA DD11–007, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 11 a.m.–5 p.m., April 21, 2011 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to Be Discussed: The meeting will include the initial review, discussion, and evaluation of "Pilot for State-specific Cross-Sectional Surveillance of Persons with Rare Disorders and Longitudinal Assessment of Outcomes, FOA DD11–004, and Pilot Longitudinal Data Collection to Inform Public Health—Fragile X Syndrome, FOA DD11–007."

Contact Person for More Information: Donald Blackman, PhD, Scientific Review Officer, Extramural Research Program Office, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, Georgia 30341, Telephone: (770) 488–3023, E-mail: *DBY7@cdc.gov.*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 7, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–5755 Filed 3–11–11; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Family History and Diamond Blackfan Anemia, DD11–010, Initial Review

Correction: This notice was published in the **Federal Register** on January 21, 2011, Volume 76, Number 14, Page 3909. The date for the aforementioned meeting has been changed to the following:

DATES: April 27, 2011 (Closed).

Contact Person for More Information: Michael Dalmat, Dr.P.H., Scientific Review Officer, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, Georgia 30341, Telephone: (770) 488–6423, E-mail: *MED1@CDC.GOV.*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 7, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–5759 Filed 3–11–11; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Opportunity to Partner; Testing of Patient Litters and Patient Restraints to Proposed Test Standard

Authority: 29 U.S.C. 669.

AGENCY: NIOSH, Centers for Disease Control and Prevention (CDC),